Acción MDNA MEDICENNA THERAPEUTICS CORP.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Medicenna Therapeutics Corp.

Acciones

MDNA

CA58490H1073

Diferido Toronto S.E.
Otros sitios de cotización
 21:50:39 30/04/2024 		Varia. Cinco días. Varia. 1 de enero.
2,32 CAD +0,43 % Gráfico intradía de Medicenna Therapeutics Corp. +49,68 % +452,38 %
24/04 Medicenna Therapeutics sube un 13% tras anunciar que presentará dos resúmenes MT
16/04 Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
Canadian Investment Regulatory Organization Trade Resumption - MDNA
Canadian Investment Regulatory Organization Trading Halt - MDNA
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding
Medicenna Therapeutics Up 13% After Flagging Presentations
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research
Medicenna Brief: Presenting Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of Phase 1/2 ABILITY-1 Study at 2024 Annual Meeting of the AACR
Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today
Medicenna Brief: Comes After Its Shares Lost Near 12% today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And Masked Bi-Functional Anti-PD1-IL2 Superkine
Medicenna Brief: Says Presented Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study
Medicenna Therapeutics Down 11% as it Presents Updated Preclinical Data on MDNA113 at AACR 2024
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Medicenna to Present at the 2024 Bloom Burton and Co. Healthcare Investor Conference
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Medicenna Brief: Says to Provide Clinical Update on MDNA11 ABILITY-1 Trial at Upcoming American Association for Cancer Research Annual Meeting
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción MDNA
  4. Noticias Medicenna Therapeutics Corp.
  5. Otros idiomas